CymaBay Therapeutics Employee Directory
Pharmaceutical ManufacturingCalifornia, United States11-50 Employees
CymaBay Therapeutics is a clinical-stage biopharmaceutical company pursuing therapies for liver diseases and other chronic conditions with limited treatment options. The company is based in Newark, California. Its lead candidate, Seladelpar, is an oral agent targeting the PPARδ pathway and is being developed for primary biliary cholangitis, an autoimmune liver disease. Beyond Seladelpar, CymaBay is advancing additional investigational products and lead candidates for liver and other chronic diseases. In December 2025, the company announced a collaboration with Glencoe Software to digitally transform a pathology review workflow, a step aimed at supporting an NDA-enabling clinical trial ahead of schedule.